Passa al contenuto
Merck
Tutte le immagini(2)

Documenti fondamentali

915408

Sigma-Aldrich

NanoFabTx PEGylated nanoparticle formulation screening kit

Sinonimo/i:

NanoFabTx reagent kit, Nanoparticle synthesis kit, PEGylated nanoformulations

Autenticatiper visualizzare i prezzi riservati alla tua organizzazione & contrattuali


About This Item

Codice UNSPSC:
12161503
NACRES:
NA.23

Descrizione

Kit components :
PEGPLGA-50L (912808-500mg)
PEGPLGA-75L (913049-500mg)
PEGPLA-L (913308-500mg)
PEGPCL-H (912549-500mg)
Stabilizer - P (913448-10g)

Materials screening kit, for synthesis of PEGylated polymeric nanoparticles

Livello qualitativo

applicazioni

advanced drug delivery

Temperatura di conservazione

2-8°C

Descrizione generale

NanoFabTx PEGylated nanoparticle formulation screening kit contains optimized reagents and protocols for nanoprecipiation and microfluidic-based synthesis of polymer nanoparticles. The kit provides rationally selected PEGylated PLGA, PLA, and PCL polymers, which are widely used in drug delivery systems for controlled drug release of many different types of therapeutic molecules. This reagent kit can be combined with the NanoFabTx Microfluidic - nano device kit (Cat.No. 911593) for microfluidic synthesis of polymer nanoparticles 60 to 100 nm in size.

Applicazioni

NanoFabTx PEGylated nanoparticle formulation screening kit is designed for the synthesis of specifically sized, hydrophobic drug encapsulated biodegradable PEGylated polymer nanoparticles. Our specially designed PEGylated polymers result in nanoparticles with a PEG surface coating that reduces protein absorption and prolongs circulation time, leading to slow and sustained release of the encapsulated drug. The NanoFabTx PEGylated nanoparticle formulation screening kit enables nanoparticle optimization by selection of the right polymer to achieve the desired nanoparticle size, drug encapsulation, release kinetics, and stability in systemic circulation. This kit provides reagents and protocols for nanoprecipitation and microfluidics to synthesize 60 nm to 100 nm nanoparticles.

Caratteristiche e vantaggi

  • Provides step-by-step protocols, both for standard extrusion or microfluidic-based synthesis, developed and tested by our formulation scientists
  • Microfluidic formulation development for enhancing drug bioavailability
  • Flexible synthesis tool to create uniform and reproducible nanoparticles
  • Optimized to make nanoparticles from 60-100 nm
  • Includes 4 different PEGylated polymers to identify the optimal material

Note legali

NANOFABTX is a trademark of Sigma-Aldrich Co. LLC

Codice della classe di stoccaggio

12 - Non Combustible Liquids


Scegli una delle versioni più recenti:

Certificati d'analisi (COA)

Lot/Batch Number

It looks like we've run into a problem, but you can still download Certificates of Analysis from our Documenti section.

Se ti serve aiuto, non esitare a contattarci Servizio Clienti

Possiedi già questo prodotto?

I documenti relativi ai prodotti acquistati recentemente sono disponibili nell’Archivio dei documenti.

Visita l’Archivio dei documenti

S Freiberg et al.
International journal of pharmaceutics, 282(1-2), 1-18 (2004-09-01)
Polymer microspheres can be employed to deliver medication in a rate-controlled and sometimes targeted manner. Medication is released from a microsphere by drug leaching from the polymer or by degradation of the polymer matrix. Since the rate of drug release
Verónica Lassalle et al.
Macromolecular bioscience, 7(6), 767-783 (2007-06-02)
The controlled release of medicaments remains the most convenient way of drug delivery. Therefore, a wide variety of reports can be found in the open literature dealing with drug delivery systems. In particular, the use of nano- and microparticles devices
Nazila Kamaly et al.
Chemical Society reviews, 41(7), 2971-3010 (2012-03-06)
Polymeric materials have been used in a range of pharmaceutical and biotechnology products for more than 40 years. These materials have evolved from their earlier use as biodegradable products such as resorbable sutures, orthopaedic implants, macroscale and microscale drug delivery
Byung Kook Lee et al.
Advanced drug delivery reviews, 107, 176-191 (2016-06-06)
Poly(d,l-lactic acid) (PLA) has been widely used for various biomedical applications for its biodegradable, biocompatible, and nontoxic properties. Various methods, such as emulsion, salting out, and precipitation, have been used to make better PLA micro- and nano-particle formulations. They are

Global Trade Item Number

SKUGTIN
915408-1EA4061841722908
915408-1KT4065266037265

Il team dei nostri ricercatori vanta grande esperienza in tutte le aree della ricerca quali Life Science, scienza dei materiali, sintesi chimica, cromatografia, discipline analitiche, ecc..

Contatta l'Assistenza Tecnica.